Go Pro
→ NASA's ISS Replacement Could Go to This Tiny Space Firm (From Behind the Markets) (Ad)tc pixel Free RVMDW Stock Alerts

Revolution Medicines (RVMDW) Competitors

Revolution Medicines logo
$10.13 +0.31 (+3.16%)
As of 11:01 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

RVMDW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Revolution Medicines stock or one of its competitors? Revolution Medicines's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Revolution Medicines compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Revolution Medicines (NASDAQ:RVMDW) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Revolution Medicines N/A N/A N/A

In the previous week, Alvotech's average media sentiment score of 0.00 equaled Revolution Medicines'average media sentiment score.

Company Overall Sentiment
Alvotech Neutral
Revolution Medicines Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.95MN/AN/AN/AN/A
Revolution MedicinesN/AN/AN/AN/AN/A

Summary

Alvotech beats Revolution Medicines on 1 of the 1 factors compared between the two stocks.

How does Revolution Medicines compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Revolution Medicines (NASDAQ:RVMDW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Revolution Medicines N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Revolution MedicinesN/AN/AN/AN/AN/A

In the previous week, Apollomics' average media sentiment score of 0.00 equaled Revolution Medicines'average media sentiment score.

Company Overall Sentiment
Apollomics Neutral
Revolution Medicines Neutral

Summary

Apollomics beats Revolution Medicines on 1 of the 1 factors compared between the two stocks.

How does Revolution Medicines compare to Aravive?

Revolution Medicines (NASDAQ:RVMDW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Revolution Medicines' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Revolution Medicines Neutral
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
Revolution MedicinesN/A N/A N/A
Aravive N/A N/A N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution MedicinesN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Summary

Aravive beats Revolution Medicines on 2 of the 2 factors compared between the two stocks.

How does Revolution Medicines compare to bioAffinity Technologies?

Revolution Medicines (NASDAQ:RVMDW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution MedicinesN/AN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

In the previous week, bioAffinity Technologies had 2 more articles in the media than Revolution Medicines. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.73 indicating that Revolution Medicines is being referred to more favorably in the media.

Company Overall Sentiment
Revolution Medicines Neutral
bioAffinity Technologies Negative

Company Net Margins Return on Equity Return on Assets
Revolution MedicinesN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

Summary

bioAffinity Technologies beats Revolution Medicines on 2 of the 3 factors compared between the two stocks.

How does Revolution Medicines compare to BioVie?

BioVie (NASDAQ:BIVIW) and Revolution Medicines (NASDAQ:RVMDW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
Revolution Medicines N/A N/A N/A

In the previous week, BioVie had 2 more articles in the media than Revolution Medicines. MarketBeat recorded 2 mentions for BioVie and 0 mentions for Revolution Medicines. BioVie's average media sentiment score of 0.82 beat Revolution Medicines' score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company Overall Sentiment
BioVie Positive
Revolution Medicines Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
Revolution MedicinesN/AN/AN/AN/AN/A

Summary

BioVie beats Revolution Medicines on 2 of the 2 factors compared between the two stocks.

Get Revolution Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVMDW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVMDW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVMDW vs. The Competition

Export
MetricRevolution MedicinesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.91B$7.27B$13.03B
Dividend YieldN/A3.63%2.52%12.57%
P/E RatioN/A14.13274.9525.63
Price / SalesN/A1,446.16669.1697.27
Price / CashN/A113.2977.8052.76
Price / BookN/A15.0110.326.26
Net IncomeN/A-$22.82M$3.49B$360.12M
7 Day Performance-1.84%-2.72%-1.33%-0.42%
1 Month Performance-15.79%-7.12%-3.71%-3.75%
1 Year Performance3,497.30%29.24%14.41%4.84%

Revolution Medicines Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVMDW
Revolution Medicines
N/A$10.13
+3.2%		N/A+4,331.8%$0.00N/AN/A378
ALVOW
Alvotech
N/A$0.27
flat		N/A-81.9%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
flat		N/A-39.3%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.30
-5.9%		N/A+284.4%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RVMDW) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Wall Street Legend: “I've discovered a fatal flaw built into Elon's AI model”
Wall Street veteran Marc Chaikin says he's found a fatal flaw built into Elon Musk's AI model and every fronti...
Chaikin Analytics | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Congress Passes Landmark Digital Asset Law Wall Street Is Watching
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...
Awesomely | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
The AI Infrastructure Rush Is ON — Watch VDTA
Vertical Data Inc. (OTCQB: VDTA) is targeting the layers beneath the AI boom - GPU hardware and financing, man...
Trading Wire | Sponsoredtc pixel